Compare Amphastar Pharmaceuticals Inc (AMPH) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Weibo Corp — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Weibo Corp trades at $7.77 (market cap $1.93B). The key difference: Weibo Corp is far larger — about 2.2× Amphastar Pharmaceuticals Inc's market cap, and Weibo Corp pays a 7.65% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | WB | |
|---|---|---|
Market Cap | $863.95M | $1.93B |
Sector | Health | Media |
52-Week High | $30.81 | $12.83 |
52-Week Low | $16.87 | $7.20 |
Enterprise Value | $1.26B | $1.20B |
Dividend Yield | — | 7.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Weibo (WB) trades at $7.94, up 0.76% today, with neutral technical signals and strong fundamental metrics including a low P/E of 5.55 and robust 21.15% net income margin. Recent earnings show three consecutive quarterly misses but Q2 2026 results are pending. The company maintains solid cash flow generation with $519M operating cash flow in 2025, while analyst sentiment is mixed with 45% buy ratings.
WB presents value opportunity with discounted valuation metrics and strong profitability, though competitive pressures from Douyin and WeChat create headwinds. The stock's 8% dividend yield and cash-rich balance sheet provide downside protection, but investor sentiment remains cautious pending Q2 earnings results on August 19, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
